Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Division of Disease Control and Public Health Response, Colorado Department of Public Health and Environment, Denver, Colorado, USA.
Clin Infect Dis. 2023 Aug 22;77(4):629-637. doi: 10.1093/cid/ciad214.
Nontuberculous mycobacteria (NTM) cause pulmonary (PNTM) and extrapulmonary (ENTM) disease. Infections are difficult to diagnose and treat, and exposures occur in healthcare and community settings. In the United States, NTM epidemiology has been described largely through analyses of microbiology data from health departments, electronic health records, and administrative data. We describe findings from a multisite pilot of active, laboratory- and population-based NTM surveillance.
The Centers for Disease Control and Prevention's Emerging Infections Program conducted NTM surveillance at 4 sites (Colorado, 5 counties; Minnesota, 2 counties; New York, 2 counties; and Oregon, 3 counties [PNTM] and statewide [ENTM]) from 1 October 2019 through 31 March 2020. PNTM cases were defined using published microbiologic criteria. ENTM cases required NTM isolation from a nonpulmonary specimen, excluding stool and rectal swabs. Patient data were collected via medical record review.
Overall, 299 NTM cases were reported (PNTM: 231, 77%); Mycobacterium avium complex was the most common species group. Annualized prevalence was 7.5/100 000 population (PNTM: 6.1/100 000; ENTM: 1.4/100 000). Most patients had signs or symptoms in the 14 days before positive specimen collection (ENTM: 62, 91.2%; PNTM: 201, 87.0%). Of PNTM cases, 145 (62.8%) were female and 168 (72.7%) had underlying chronic lung disease. Among ENTM cases, 29 (42.6%) were female, 21 (30.9%) did not have documented underlying conditions, and 26 (38.2%) had infection at the site of a medical device or procedure.
Active, population-based NTM surveillance will provide data for monitoring the burden of disease and characterize affected populations to inform interventions.
非结核分枝杆菌(NTM)可引起肺部(PNTM)和肺外(ENTM)疾病。此类感染的诊断和治疗具有一定难度,并且常发生于医疗保健和社区环境中。在美国,NTM 流行病学主要通过对来自卫生部门、电子健康记录和行政数据的微生物数据进行分析来描述。我们描述了一项多地点、主动、基于实验室和人群的 NTM 监测的试点研究结果。
美国疾病控制与预防中心新兴传染病项目于 2019 年 10 月 1 日至 2020 年 3 月 31 日期间在 4 个地点(科罗拉多州的 5 个县、明尼苏达州的 2 个县、纽约州的 2 个县和俄勒冈州的 3 个县[PNTM]和全州[ENTM])开展 NTM 监测。肺部 NTM 病例的定义采用已发表的微生物学标准。肺外 NTM 病例需从非肺部标本中分离出 NTM,粪便和直肠拭子除外。通过病历回顾收集患者数据。
共报告了 299 例 NTM 病例(PNTM:231 例,77%);最常见的菌种群为鸟分枝杆菌复合体。年患病率为 7.5/100000 人口(PNTM:6.1/100000;ENTM:1.4/100000)。大多数患者在阳性标本采集前 14 天出现体征或症状(ENTM:62 例,91.2%;PNTM:201 例,87.0%)。在 PNTM 病例中,145 例(62.8%)为女性,168 例(72.7%)患有潜在的慢性肺部疾病。在肺外 NTM 病例中,29 例(42.6%)为女性,21 例(30.9%)无已知基础疾病,26 例(38.2%)感染发生于医疗器械或手术部位。
主动、基于人群的 NTM 监测将提供疾病负担监测数据,并描述受影响人群特征,以为干预措施提供信息。